[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"episodic-migraine\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:episodic-migraine":496},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,44,71,93,121,147,169,194,218,244,273,295,320,350,378,408,437,460,482],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100493917",false,"NCT05711394","A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine","A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 Years of Age.","Inclusion Criteria:\n\n* Weight is \\>= 20 kg (44 lbs) and \\\u003C 135 kg (298 lbs).\n* History of episodic migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders (ICHD) -3 (2018) for at least 6 months.\n* Participant has to have 4 to 14 migraine days and \\\u003C 15 headache days in the 28-day baseline period per eDiary.\n* To be eligible for the PK substudy, participants must be 6 to 11 years of age (inclusive), with a history of migraine (consistent with a diagnosis according to the ICHD-3 \\[2018\\]) and per investigator judgment is appropriate to receive preventive treatment for migraine.\n\nExclusion Criteria:\n\n* History of migraine brainstem aura, hemiplegic migraine, or retinal migraine as defined by ICHD-3 (2018).\n* Have a current diagnosis of chronic migraine as defined by ICHD-3 (2018).\n* Have a current diagnosis of new daily persistent headache, trigeminal autonomic cephalgia (e.g., cluster headache), or painful cranial neuropathy as defined by ICHD-3 (2018).","ALL","6 Years","17 Years",{"count":19,"type":20},450,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. A number of treatments are available for adults with migraine but there are limited approved treatments available for pediatric participants. The main goal of the study is to evaluate the safety and efficacy (how well treatment works) of a low-dose and high-dose of atogepant in pediatric participants between the ages of 6 and 17.\n\nAtogepant is a medicine currently approved to treat adults with migraine (0 to 14 migraine days per month) and is being studied in pediatric participants between the ages of 6 and 17 with a history of episodic migraine. This is a Phase 3, randomized, double-blind study of atogepant in participants with a history of episodic migraine with an open-label pharmacokinetic substudy. Eligible participants will be randomized into 6 different groups. Participants between the ages of 12 and 17 will be randomized to receive placebo, low-dose atogepant, or high-dose atogepant for 12 weeks. Participants between the ages of 6 and 11 will also be randomized to receive placebo, low-dose atogepant, or high-dose atogepant for 12 weeks. The specific atogepant doses to be used in participants between the ages of 6 and 11 will be determined after the PK substudy is complete. Around 450 participants will be enrolled in approximately 100 sites worldwide.\n\nPlacebo, low-dose atogepant, and high-dose atogepant are given as a tablet to take by mouth once a day. At the end of Week 12, participants will either undergo a follow-up visit 4 weeks after last study treatment or join an extension study where they can continue to receive atogepant for another 52 weeks.\n\nThere may be a bigger responsibility for participants in this study. Participants will attend regular visits during the study at a hospital or clinic. The effects of treatment will be checked by medical assessments, blood tests, checking for side effects, and completing questionnaires.",[26],"Episodic Migraine",[26,28,29,30],"Atogepant","QULIPTA","AGN-241689","RECRUITING","2026-06-29",{"date":34,"type":35},"2026-07-01","ACTUAL",{"date":37,"type":35},"2023-05-01",{"date":39,"type":20},"2028-05",{"name":41,"class":42},"AbbVie","INDUSTRY",98,{"id":45,"slug":4,"hasResults":10,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":10,"sex":15,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100533747","NCT06229834","Chiropractic Care for Episodic Migraine","Inclusion Criteria\n\n* Age 18-65 years\n* Confirmed diagnosis of migraine with or without aura which does not meet criteria for chronic migraine according to the International Classification for -Headache Disorders (ICHD)-3 guidelines at the screening visit with the study physician\n* History of migraines dating for at least one year\n* Completion of at least 26 headache diary days out of 28\n* Confirmed migraine frequency ≥4 to ≤13 days per month during a run-in period\n* If use of medication is applicable, dose must be stable for 2 months prior to study enrollment\n* If use of medication for non-migraine pain condition is applicable (with the exception of episodic tension type headache), dose must be stable for 2 months prior to study enrollment\n* Willing and able to complete all study procedures and be randomized to either of the two intervention groups\n* Fluency in English\n* Confirmed access to and proficiency with use of a smartphone, computer, and\u002For tablet\n* Working email address or willingness to create an email account for the study\n\nExclusion Criteria\n\n* Non-Veterans (VAMC only)\n* Received botulinum toxin treatment for headache and\u002For neck pain within the 4 months prior to the start of the baseline phase\n* Received chiropractic care for any condition within the 3 months prior to the start of the baseline phase\n* Received behavioral interventions (e.g., cognitive behavioral therapy, acceptance and commitment therapy, mindfulness, relaxation techniques, hypnosis) within the past 3 months)\n* Used neuromodulation (i.e., \"headache devices\"), procedures for migraine prevention within the 2 months before the baseline period, or investigational medications or headache devices for at least 90 days prior to screening\n* Diagnosis of medication overuse headache according to the ICHD-3 guidelines at the screening visit with the study physician\n* Traumatic Brain Injury ≤ 1 year before screening visit or worsening of migraine as noted by the screening study physician\n* Head or neck trauma within the past year causing neurological or musculoskeletal signs or symptoms requiring treatment\n* Any medical, neurologic, or psychiatric condition that the screening study physician deems would lead to difficulty complying with the protocol or negatively impact the safety profile of the interventions\n* Psychiatric hospitalization in the last 6 months\n* Receiving hospice or palliative care\n* History of carotid or vertebral artery dissection\n* Presence of carotid bruits\n* Presence of contraindications (relative or absolute) for spinal manipulation or mobilization where these procedures cannot be modified for safe administration and are consistent with those published by the World Health Organization (WHO) guidelines, including but not limited to:\n* Local spinal hypermobility\u002Finstability\n* Conditions causing general spinal hypermobility, such as Marfan, Ehlers-Danlos syndrome, and Osteogenesis imperfecta\n* Malignancy of the spine or spinal cord\n* Frank disc herniation with signs of progressive neurological deficit\n* Spinal or intracanalicular hematomas Inflammatory spondyloarthropathies such as rheumatoid arthritis\n* Spinal fractures or dislocations\n* Avascular necrosis in an area of proposed joint manipulation\n* Bone-weakening disorders affecting the spine, such as benign bone tumors, infection, or osteoporosis\n* Vertebrobasilar insufficiency syndrome\n* Aneurysm involving a major blood vessel in an area of potential joint manipulation\n* History of stroke\n* Anticoagulant therapy or blood disorders cause significant bleeding tendency\n* Cervical spine congenital anomalies that affect the stability or neurologic integrity of the individual or history of cervical spine surgery\n* Either self-reported current alcohol or substance use disorder or current alcohol or substance use disorder documented by a treating medical provider within the past 6 months\n* Hormone replacement therapy for less than six months, or if prescriptions greater than 6 months in duration must be at a stable dose\n* Significant cognitive impairment that would impair participation in the trial\n* Currently pregnant or intention to become pregnant within the next six months","18 Years","65 Years",{"count":52,"type":20},60,[54],"NA","Migraine, a chronic intermittent headache disorder, ranks in the top five causes of years lived with disability. One promising non-pharmacologic and integrative treatment for migraine may be chiropractic care due to the co-occurrence of migraine and musculoskeletal complaints. The goal of this application is to perform a pilot study of chiropractic care for episodic migraine to help inform the design of a future, full-scale pragmatic effectiveness trial.",[26],[58,59],"migraine","headache disorder","2026-06-24",{"date":62,"type":35},"2026-06-26",{"date":64,"type":35},"2025-03-22",{"date":66,"type":20},"2027-04-30",{"name":68,"class":69},"Brigham and Women's Hospital","OTHER",1,{"id":72,"slug":4,"hasResults":10,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":10,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":92},"100594381","NCT07018700","A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine","A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Clinical Trial With Extension Period to Evaluate the Efficacy and Safety of Xeomin® Injections for the Prevention of Episodic Migraine","MINT-E","Inclusion Criteria:\n\n* Participant has a diagnosis of EM with or without aura according to current International Classification of Headache Disorders (Edition 3 and Edition 4 alpha) criteria for ≥ 12 months and is able to distinguish migraine headaches from all other types of headaches;\n* Participant age \\\u003C 50 years at the time of migraine onset;\n* Participant meeting the following headache and migraine day criteria in each of the 3 months prior to screening: history of ≤ 14 headache days per month and history of 6 to 14 migraine days per month; and\n* During the last 28 days of the screening period, participant experiencing: ≤ 14 headache days and 6 to 14 migraine days that qualify as such per the headache diary.\n\nExclusion Criteria:\n\n* Diagnosis of chronic migraine;\n* Diagnosis of other primary headache types, except tension-type headache, which is permitted;\n* Diagnosis of aura without headache, migraine with brainstem aura, hemicrania continua, hypnic headache, hemiplegic migraine, retinal migraine, persistent aura without infarction, migraine aura-triggered seizure, or previous migrainous infarction;\n* Diagnosis of secondary headache types, except medication overuse headache, which is permitted;\n* Currently taking \\> 1 prescribed drug for the preventive treatment of migraine;\n* Discontinuation of anti-calcitonin gene-related peptide (CGRP) \u002F anti-CGRP receptor monoclonal antibody treatment less than 5 months prior to screening.",{"count":79,"type":20},990,[23],"In this clinical trial, participants with episodic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections.\n\nTrial details include:\n\n* Trial duration: 52 to 55 weeks;\n\n  * Screening period: 4 to 5 weeks;\n  * Treatment duration: 4 treatments, each about 12 weeks apart; and\n* Visit frequency: about every 4 weeks, 14 visits in total. The first and last visit and the 4 treatment visits are on-site, the other 8 visits are remote by phone \u002F video call.",[26],"2026-06-22",{"date":85,"type":35},"2026-06-25",{"date":87,"type":35},"2025-08-21",{"date":89,"type":20},"2027-10",{"name":91,"class":42},"Merz Therapeutics GmbH",108,{"id":94,"slug":4,"hasResults":10,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":10,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":21,"phases":101,"briefSummary":102,"conditions":103,"keywords":104,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":70},"100641692","NCT07661888","Neurofeedback for Episodic Migraine","Effectiveness of Neurofeedback for Reducing the Frequency and Severity of Episodic Migraine","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Diagnosis of episodic migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3), with or without aura.\n* History of medium to high-frequency episodic migraine, defined as 5-14 migraine days per month during the 3 months prior to enrollment.\n* Ability and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Diagnosis of chronic migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3), defined as ≥15 headache days per month for more than 3 months, with at least 8 migraine days per month.\n* History of severe psychiatric disorders (e.g., schizoaffective disorder, bipolar disorder, major depressive episode with psychotic features, or other non-organic psychotic disorders) requiring psychiatric treatment within the 6 months prior to enrollment.\n* History of brain injury or other neurological conditions that contraindicate the use of neurofeedback.",{"count":100,"type":20},66,[54],"Background:\n\nMigraine is a highly prevalent neurological disorder and one of the leading causes of disability worldwide, particularly among women of reproductive age. It is associated with substantial clinical, psychological, and socioeconomic burden, including increased risk of vascular and psychiatric comorbidities, reduced quality of life, sleep disturbances, and decreased productivity. Neurofeedback (NF) has emerged as a promising non-pharmacological intervention aimed at promoting self-regulation of brain activity through real-time feedback and neuroplasticity mechanisms.\n\nObjective:\n\nThis study aims to evaluate the effectiveness of neurofeedback as an adjunct therapy in reducing the frequency and severity of high-frequency episodic migraine in adults. Secondary objectives include assessing changes in medication use, sleep quality, disability and functional impact, depressive symptoms, and the influence of common migraine triggers.\n\nMethods:\n\nA randomized controlled trial with two parallel groups will be conducted at the University Hospital of Salamanca. Participants will be adults (\\>18 years) diagnosed with episodic migraine (5-14 days\u002Fmonth). A total of 66 participants will be randomly assigned (1:1) to either a neurofeedback intervention group or a control group. The intervention consists of 60 neurofeedback sessions over 12 weeks, including EEG-based training aimed at reducing high beta activity (21-30 Hz) and increasing alpha activity (8-12 Hz), as well as blood volume pulse biofeedback. The control group will receive no additional intervention. Primary outcomes include migraine frequency and severity, while secondary outcomes encompass medication use, disability (MIDAS, HIT-6), sleep quality (PSQI), quality of life (MSQ), depressive symptoms (PHQ-9), and trigger-related variables. Assessments will be performed at baseline, 3 months, and 6 months. Data will be analyzed using repeated-measures mixed models (SPSS v28).\n\nExpected Results:\n\nIt is hypothesized that neurofeedback will significantly reduce migraine frequency and severity compared to control conditions, and improve associated functional, psychological, and sleep-related outcomes.\n\nConclusions:\n\nThis trial aims to provide robust evidence on the efficacy of neurofeedback as a complementary therapeutic approach for migraine, addressing the current need for well-designed randomized controlled studies in this field.",[26],[105,106,107,108,109,110,111],"neurofeedback","episodic migraine","migraine frequency","migraine severity","sleep quality","disability","quality of life","NOT_YET_RECRUITING","2026-06-16",{"date":83,"type":35},{"date":116,"type":20},"2026-11-15",{"date":118,"type":20},"2027-12-31",{"name":120,"class":69},"University of Salamanca",{"id":122,"slug":4,"hasResults":10,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":10,"sex":15,"minAge":128,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":131,"phases":4,"briefSummary":132,"conditions":133,"keywords":136,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":146},"100562468","NCT06603558","Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine","Post-marketing Surveillance Study to Evaluate the Safety and Effectiveness of Atogepant for the Prevention of Migraine in Korean Adult Patients","Atogepant PMSS","Inclusion Criteria:\n\n* Participants with migraine suitable for the treatment with atogepant according to the latest approved local label.\n* Participants prescribed atogepant in accordance with the approved local label.\n\nExclusion Criteria:\n\n* Participants with any contraindication to atogepant as listed on the latest approved local label.\n* Participants currently participating in another clinical research except observational study.","19 Years",{"count":130,"type":20},3000,"OBSERVATIONAL","Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and\u002For sensitivity to light and sound. The study will assess the safety and effectiveness of atogepant for the preventive treatment of migraine in Korean adult patients with chronic migraine or episodic migraine under routine clinical practice.\n\nAtogepant is an approved drug for preventive treatment of migraine in adults. Approximately 3000 adult participants who are prescribed atogepant by their doctors will be enrolled in this study in Korea.\n\nParticipants will receive atogepant oral tablets as prescribed by their physician. Participants will be followed for up to week 12.\n\nThere is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.",[134,26,135],"Chronic Migraine","Migraine",[134,26,135,28,137,138],"Qulipta","Aquipta",{"date":140,"type":35},"2026-06-18",{"date":142,"type":35},"2024-09-24",{"date":144,"type":20},"2029-05",{"name":41,"class":42},4,{"id":148,"slug":4,"hasResults":10,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":154,"targetDuration":4,"studyType":21,"phases":156,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":168},"100508200","NCT05897320","A Study of Eptinezumab in Pediatric Participants With Episodic Migraine","Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Eptinezumab in Paediatric Patients (6 to 17 Years) for the Preventive Treatment of Episodic Migraine","PROSPECT-1","Inclusion Criteria:\n\n* Diagnosis of migraine (with or without aura) according to the International Classification of Headache Disorders, 3rd edition (ICHD-3; in the opinion of the investigator) with history of migraine headaches of at least 6 months prior to the Screening Visit.\n* During the 28-day screening period, the participant (and their parent\u002Fcaregiver, when applicable) must adequately complete the headache eDiary (≥23 of the 28 days) following the day of the Screening Visit.\n* During the 28-day screening period, the participant must have ≤14 headache days, of which at least 4 are migraine days as documented in the eDiary.\n\nExclusion Criteria:\n\n* History or diagnosis of chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or unusual migraine subtypes (previously referred to as complicated migraine), such as hemiplegic migraine (sporadic and familial), migraine with brainstem aura, recurrent painful ophthalmic neuropathy, or migraine with neurological accompaniments that are not typical of migraine aura (diplopia, altered consciousness, or long duration, e.g., \\>60 min).\n* History of moderate or severe head trauma or other neurological disorder or systemic medical disease that is, in the investigator's opinion, likely to affect the functions of the central nervous system.\n* Current psychiatric condition that is uncontrolled and\u002For untreated for a minimum of 6 months prior to the Screening Visit. Participants with a lifetime history of psychosis and\u002For mania are excluded.\n* Any other disorder for which the treatment takes priority over treatment of migraine or is likely to interfere with study treatment or impair treatment compliance.\n\nOther inclusion and exclusion criteria may apply.",{"count":155,"type":20},315,[23],"The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.",[26],"2026-06-11",{"date":161,"type":35},"2026-06-12",{"date":163,"type":35},"2023-06-08",{"date":165,"type":20},"2027-08-31",{"name":167,"class":42},"H. Lundbeck A\u002FS",65,{"id":170,"slug":4,"hasResults":10,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":10,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":21,"phases":176,"briefSummary":178,"conditions":179,"keywords":180,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":187,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":70},"100495701","NCT05734625","Efficacy of Nerve Blocks for Episodic Migraine","A Randomized Trial of Bilateral Greater Occipital Nerve Blocks Versus Ten Peripheral Nerve Blocks for Acute Relief and Prophylaxis of Episodic Migraine","Inclusion Criteria:\n\n* Suffering from episodic migraines with and without aura occurring at least four times a month but less than 15 times a month at a severity of 5\u002F10 pain level or greater.\n* Willing to not start or stop any new medication to treat or prevent migraines during the six months of the trial.\n* History fits the definition of migraine:\n\n  * Have a history of episodic headache lasting 4-72 hours with at least 2 of the 4 following: unilateral location, pulsating\u002Fthrobbing quality, moderate-severe intensity, aggravation by\u002Fcausing avoidance of routine physical activity, and\n  * Have a history of at least one of the following: nausea and\u002For vomiting, photophobia (seek out a dark room during a headache because that feels better), phonophobia (seek out a quiet environment during a headache because that feels better)\n\nExclusion Criteria:\n\n* Headache in cheeks (infraorbital nerve distribution) in addition to scalp distribution.\n* Women who report being currently pregnant or lactating or are of child-bearing potential or are likely to become pregnant during the medication phase and are unwilling to use a reliable form of contraception. Acceptable forms include:\n\n  * Hormonal methods, such as birth control pills, patches, injections, vaginal ring, or implants\n  * Barrier methods (such as a condom or diaphragm) used with a spermicide (a foam, cream, or gel that kills sperm)\n  * Intrauterine device (IUD)\n  * Total hysterectomy or tubal ligation\n  * Abstinence (no sex)\n* Allergy or documented contraindication to amide anesthetics (bupivacaine, lidocaine, ropivacaine, prilocaine, mepivacaine, etidocaine or levobupivacaine) or corticosteroids\n* Previously received peripheral nerve blocks (PNBs)\n* Currently anticoagulated\n* Currently receiving Botox for migraine prophylaxis\n* Started on new medication in the prior two months with known migraine-preventive efficacy or planning to start any new medication during the study\n* Currently using opiate medications for pain\n* History of drug or alcohol abuse within the prior two years\n* Have unstable medical or surgical diseases that could impair participation in this study\n* History of craniotomies, burr holes, skull fractures and\u002For have open skull defects\n* Patients with implanted nerve stimulators or shunts\n* Phobia of needles\n* Active skin or soft tissue infection overlying injection sites\n* Diagnosis of medication overuse, cervicogenic, post-traumatic, or cluster headaches or history on pre-enrollment questionnaire of cluster headache symptoms.",{"count":52,"type":20},[177],"PHASE2","The purpose of this study is to see how well blocking two to ten of the scalp nerves (that give feeling to the scalp and are painful during migraine headaches) with bupivacaine anesthetic (numbing medication) and low dose methylprednisolone (cortisone-like medicine or steroid) work for treating and preventing migraines. Our hypothesis is that the pain of most episodic migraine headaches can be eliminated and prevented for months by blocking the nerves that give pain sensation during a migraine.",[26],[106,181,182,183,184,185,186],"peripheral nerve block","greater occipital nerve block","lesser occipital nerve block","auriculotemporal nerve block","supraorbital nerve block","supratrochlear nerve block",{"date":113,"type":35},{"date":189,"type":35},"2023-07-10",{"date":191,"type":20},"2027-07",{"name":193,"class":69},"Mayo Clinic",{"id":195,"slug":4,"hasResults":10,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":10,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":201,"targetDuration":203,"studyType":131,"phases":4,"briefSummary":204,"conditions":205,"keywords":207,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":217},"100600915","NCT07103694","i-NEED: NEw migrainE Drugs Database","Italian Real-life Multicenter Observational Study on Efficacy, Tolerability, and Safety of Innovative Drugs (Monoclonal Antibodies, Gepants, Ditans, Sumatriptan-naproxen) for Preventive or Acute Migraine Treatment.","i-NEED","Inclusion Criteria:\n\n* Age more or equal 18 years;\n* Males and females;\n* Willingness to sign the informed consent;\n* Episodic migraine for the use of drug indicated for migraine attack\n* High frequency episodic migraine, at least 8 days per month of disabling migraine in the past 3 months;\n* Chronic migraine, according to the ICHD-III criteria;\n\nExclusion Criteria:\n\n* Other headaches different than migraine;\n* Known intolerance to the eccipients;\n* Vascular disease or Raynaud.",{"count":202,"type":20},2641,"3 Years","Approved by the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) starting in 2018, anti-CGRP monoclonal antibodies (anti-CGRP mAbs) represent the first true revolution in the preventive treatment of migraine due to their selectivity and specificity. To date, four anti-CGRP mAbs have been developed for the preventive treatment of migraine: eptinezumab, erenumab, fremanezumab, and galcanezumab.Anti-CGRP mAbs constitute not only the first specific and selective treatment for the prevention of migraine but also the most extensively studied pharmacological category in this field, considering the vast and complex populations examined. The clinical effects of the various mAbs are substantially comparable and are characterized by several fundamental aspects:\n\n* High efficacy in both episodic and chronic migraine, with the presence of super-responders who experience a reduction in the average monthly number of migraine days of \\>75% (or even 100%) compared to before treatment.\n* Efficacy that is independent of the clinical form of migraine - with or without aura - and regardless of whether there is analgesic overuse.\n* Efficacy maintained even in the presence of depressive or anxious comorbidities.\n* Rapid onset of action (even more pronounced with eptinezumab), with the therapeutic effect appearing within the first week in most cases.\n* Excellent tolerability with an absence of class-specific adverse events.\n* Outstanding treatment adherence and a very low rate of treatment discontinuation in the long term. It should also be noted that the development of anti-drug antibodies or neutralizing antibodies to anti-CGRP mAbs is rare and does not significantly impact the efficacy or tolerability of treatment. Future clinical practice will need to clarify several additional aspects, such as: 1) whether treatment with anti-CGRP mAbs can modify the course of migraine; 2) the appropriate approach regarding any traditional preventive treatment (whether to continue or discontinue it); 3) the definition of the characteristics of non-responders; 4) the definition of patients with a delayed response to treatment.\n\nGepants are oral antagonists of the CGRP receptor. Among the four gepants synthesized so far (atogepant, rimegepant, ubrogepant, zavegepant), atogepant and rimegepant are currently available in Italy. Atogepant has proven to be an effective and well-tolerated option for the prevention of episodic and chronic migraines. Rimegepant is effective for both acute treatment and prevention of migraines, with a favorable safety profile and flexible oral administration. Lasmiditan is the first ditan effective for migraine attack and it represents a new therapeutic option for patients with contraindications to triptans, due to the presence of vascular risk factors, or for patients who experience undesirable side effects with these, thus increasing the therapeutic possibilities for the symptomatic treatment of migraine. The combination of sumatriptan 85 mg and naproxen sodium 500 mg is indicated for the acute treatment of migraine attacks in adult patients for whom sumatriptan monotherapy is insufficient.",[26,134,206],"Medication Overuse Headache",[208],"migraine, anti-CGRP monoclonal antobodies, gepants, ditans, sumatriptan and naproxen combination","2026-06-09",{"date":159,"type":35},{"date":212,"type":35},"2022-03-24",{"date":214,"type":20},"2026-12-31",{"name":216,"class":69},"IRCCS San Raffaele Roma",2,{"id":219,"slug":4,"hasResults":10,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":10,"sex":15,"minAge":49,"maxAge":225,"enrollmentInfo":226,"targetDuration":4,"studyType":21,"phases":228,"briefSummary":229,"conditions":230,"keywords":231,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":242,"locationsCount":70},"100631081","NCT07496034","Efficacy of Gou-Teng-San (GTS) in Patients With Episodic Migraine","\"Efficacy of Gou-Teng-San (GTS) in Patients With Episodic Migraine: A Double-Blind Randomized Controlled Trial\" (GTSEM Trial)","GTSEM","Inclusion Criteria:\n\n* Adults aged 18 to 70 years.\n* History of episodic migraine for at least 12 months before screening, meeting the International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria, or clinically diagnosed migraine with no more appropriate ICHD-3 diagnosis.\n* During the 28-day screening period, participants must meet criteria for episodic migraine, defined as headache occurring on \\>=6 and \\\u003C=14 days, of which \\>=4 days meet at least 1 of the following: (1) ICHD-3 criteria C and D for 1.1 migraine without aura; (2) ICHD-3 criteria B and C for 1.2 migraine with aura; (3) probable migraine (missing 1 migraine criterion); or (4) headache considered to be migraine based on a positive response to migraine-specific acute treatment (e.g., a triptan or an ergotamine derivative).\n* Not receiving preventive migraine medication for at least 5 half-lives before enrollment, or receiving no more than 1 preventive migraine medication at a stable dose and regimen for at least 2 months before informed consent, whether for migraine or another medical condition (e.g., propranolol for hypertension).\n* Body mass index (BMI) between 17.5 and 37.5 kg\u002Fm2, and body weight between 35 and 120 kg.\n* Adequate compliance with headache diary completion during screening, defined as completion on at least 24 of 28 days (\\>=85%), with diary data considered acceptable by the investigator.\n* Able to comply with study restrictions and complete all protocol-required study procedures.\n* Able to understand and sign the informed consent form.\n* No major cardiovascular, hepatic, or renal disease.\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to Gou-Teng-San or any of its ingredients.\n* Receipt of botulinum toxin type A injections in the head, face, or neck for any reason within 4 months before screening.\n* Use of opioid-containing or barbiturate-containing medications on more than 4 days per month.\n* Lack of efficacy after at least 3 months of treatment at accepted migraine treatment doses in 2 or more of the following preventive medication classes: (1) topiramate or valproic acid; (2) flunarizine; (3) amitriptyline, venlafaxine, or duloxetine; (4) atenolol or propranolol.\n* Use of migraine treatment interventions within 2 months before screening, such as nerve block or transcranial magnetic stimulation.\n* Clinically significant hematologic, cardiac, renal, endocrine, pulmonary, gastrointestinal, urinary, neurologic, hepatic, ophthalmologic, psychiatric, or other disease that, in the investigator's judgment, would interfere with study participation or study procedures.\n* Participation in another clinical trial of a drug or medical device within 2 months before screening, or within 5 half-lives of the investigational product used in that trial, whichever is longer.\n* Use of other Chinese herbal medicines within 4 weeks before screening.\n* Previous exposure to monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway or CGRP receptor antagonists.\n* History of alcohol or drug abuse within the past 2 years.\n* Women who are breastfeeding, have a positive pregnancy test at screening, or are unwilling to use contraception during the study if of childbearing potential.\n* Any other condition or circumstance that, in the investigator's judgment, would make the participant unsuitable for the study or unlikely to complete the study successfully.","70 Years",{"count":227,"type":20},40,[23],"The goal of this study is to learn whether Gou-Teng-San (GTS), a traditional herbal medicine, is effective and safe for adults with episodic migraine. In this double-blind randomized controlled trial, participants with episodic migraine will be assigned by chance to a study treatment group. The study will evaluate whether GTS can reduce migraine frequency, improve migraine-related symptoms, and lessen the impact of migraine on daily life. Researchers will also monitor safety and tolerability throughout the study.",[26],[232,233,234,235],"Episodic migraine","Gou-Teng-San","Gou Teng San","Choto-san","2026-05-18",{"date":238,"type":35},"2026-05-20",{"date":240,"type":35},"2025-07-01",{"date":214,"type":20},{"name":243,"class":69},"Tsai, Chueh-Yi, MD",{"id":245,"slug":4,"hasResults":10,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":10,"sex":15,"minAge":49,"maxAge":251,"enrollmentInfo":252,"targetDuration":4,"studyType":21,"phases":254,"briefSummary":255,"conditions":256,"keywords":260,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":272},"100638204","NCT07599228","Using Virtual Reality to Teach Mindfulness to People With Migraine","Migraine Intervention Using Reality-Assisted Guided Experience","MIRAGE","Inclusion Criteria:\n\n* Adults aged 18-80\n* Diagnosed with episodic migraine and experience 4-10 migraine days\u002Fmonth\n* On a stable dose of CGRP mAb for three months prior\n* Satisfy 4 week run-in of 4-10 headaches\u002Fmonth\n* Not taking other preventive medications\n* Not pregnant, breastfeeding, or planning to become pregnant within study timeframe\n* Able and willing to use VR device\n* No history of significant psychiatric illness\n* Willing to comply with study procedures\n* English-speaking\n\nExclusion Criteria:\n\n* Medication overuse (\\>10 days\u002Fmonth)\n* Vertigo\u002Fvestibular dysfunction\n* Active psychiatric or neurological comorbidities\n* Pregnancy, breastfeeding or planning pregnancy within study timeframe\n* Significant visual\u002Fhearing\u002Fmobility impairment affecting VR use","80 Years",{"count":253,"type":20},160,[54],"The aim of this clinical trial is to learn if people with migraine can learn a type of biobehavioral therapy called Acceptance and Commitment Therapy (ACT) by using a virtual reality headset. Researchers are studying if this type of mindfulness therapy helps to decrease migraine-related disability. Participants will be randomized to treatment as usual or active virtual reality groups for four weeks. Everyone will keep symptom diaries, complete surveys, attend two clinic visits, and have two blood draws.",[257,258,259,26],"Migraine Disorders","Migraine With Aura","Migraine Without Aura",[261,58,262,263,264],"acceptance and commitment therapy (ACT)","virtual reality","mindfulness","Calcitonin Gene-Related Peptide monoclonal antibody therapy","2026-05-14",{"date":238,"type":35},{"date":268,"type":20},"2026-07",{"date":270,"type":20},"2031-01",{"name":68,"class":69},3,{"id":274,"slug":4,"hasResults":10,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":278,"eligibilityCriteria":279,"healthyVolunteers":10,"sex":15,"minAge":49,"maxAge":251,"enrollmentInfo":280,"targetDuration":4,"studyType":21,"phases":282,"briefSummary":283,"conditions":284,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":294},"100564122","NCT06625060","A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults","A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults","MERANTI","Inclusion Criteria:\n\n1. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF. Participant has provided written informed consent and signed privacy\u002Fdata protection documentation;\n2. Male or female ≥18 to 80 years of age at the time of signing the informed consent;\n3. Diagnosis of either EM or CM, per ICHD-3 criteria, for at least 12 months prior to the screening visit;\n4. Diagnosis of migraine at ≤50 years of age;\n5. Participants in the EM group: History of EM diagnosis and headache frequency (i.e. migraine and non-migraine headache): ≤14 headache days in the 4 weeks prior to randomisation on study Day 1 based on information recorded in the eDiary; migraine frequency: ≥6 migraine days in the 4 weeks prior to randomisation on study Day 1 based on information recorded in the eDiary;\n6. Participants in the CM group: History of CM diagnosis and headache frequency (i.e. migraine and non-migraine headache): ≥15 headache days in the 4 weeks prior to randomisation on study Day 1 based on information recorded in the eDiary; migraine frequency: ≥8 migraine days in the 4 weeks prior to randomisation on study Day 1 based on information recorded in the eDiary;\n7. Participant with a history of use of at least one preventive treatment for migraine.\n\nExclusion Criteria:\n\n1. History or current diagnosis of migraine with brainstem aura, retinal migraine, complications of migraine, tension-type headache, trigeminal autonomic cephalalgias, hypnic headache, hemicrania continua or new daily persistent headache;\n2. Headache attributed to another disorder (e.g. secondary headaches), except medication overuse headache (MOH);\n3. Current uncontrolled psychiatric or psychological condition, or one that could confound assessment of headaches\u002Fmigraines or interfere with study participation;\n4. Risk of self-harm or harm to others as evidenced by past suicidal behaviour or endorsing items 3, 4, or 5 on the C-SSRS at screening or Day 1.\n5. Participants presenting with a swallowing disorder of any origin which might be exacerbated by botulinum toxin treatment, such as:\n\n   \\- Grade 3 or 4 on the Dysphagia Severity Scale (severe dysphagia) with swallowing difficulties and requiring a change in diet.\n6. Clinically relevant skin condition or infection that could interfere with injection of study intervention;\n7. Participant has any medical condition or situation that would make them unsuitable for participation in the study;\n8. Participant receiving more than one allowable concomitant migraine preventive treatment;\n9. Known history of an inadequate response to \\>4 medications prescribed for the prevention of migraine (2 of which have different mechanisms of action to botulinum toxin);\n10. Use of any of the following medications in the specified timeframe prior to the screening visit:\n\n    * Botulinum toxin for migraine within 24 weeks (or for any other medical\u002Faesthetic reason within 16 weeks);\n    * Prior use of mAbs blocking CGRP pathway within 12 weeks for preventative treatment of migraine\n    * Prior use of oral CGRP receptor antagonist (gepants) for preventative treatment of migraine within 2 weeks;\n    * Anaesthetic or steroid injection in any region targeted for treatment with study medication within 4 weeks;\n    * Use of cannabidiol or other types of cannabinoids within 30 days;\n    * Use of medical device to treat migraine within 4 weeks (e.g. non-invasive neuromodulation therapies such as nerve stimulation (gammaCore), transcranial magnetic stimulation (cephaly), external trigeminal nerve stimulation, transcutaneous electrical nerve stimulation and peripheral neuroelectrical stimulation);\n    * Use of other intervention to treat migraine that is assessed to interfere with study evaluations within 4 weeks (e.g. acupuncture in the head and neck region, cranial traction, nociceptive trigeminal inhibition, occipital nerve block treatments and dental splints for headache);\n    * Use of opioids or barbiturates for more than 2 days\u002Fmonth within the last 4 weeks.\n11. Concurrent participation in another interventional clinical study (or within specified timeframe according to national or local legislation or requirements);\n12. Diagnosis of other significant pain disorders that could confound the assessment of headaches\u002Fmigraines or interfere with study participation, including but not limited to chronic pain disorders such as fibromyalgia, chronic low back pain and complex regional pain syndrome;\n13. Pregnant women, nursing women, premenopausal women, or WOCBP (i.e. not surgically sterile or 1 year postmenopausal) not willing to practice an acceptable contraceptive method, at the beginning of the study and for a minimum of 12 weeks following the administration of study treatment;\n14. Male subjects who are not vasectomised and who have female partners of childbearing potential and are not willing to use condoms with spermicide for a minimum of 12 weeks following the initial double-blind administration of the treatment;\n15. History of alcohol or drug abuse within 5 years of the screening visit (excluding medication overuse for headache);\n16. Body mass index (BMI) ≥35 kg\u002Fm² at the screening visit;\n17. Known clinically significant hypersensitivity to any of the study drugs, excipients or materials used to administer the study drug;\n18. Patients who, in the clinician's judgment, are actively suicidal, and therefore, deemed to be at significant risk for suicide.\n19. A diagnosis of a neuromuscular disorder or respiratory disorder, such as myasthenia gravis, Lambert-Eaton syndrome or amyotrophic lateral sclerosis that in the opinion of the investigator would compromise the safety of the study participant.",{"count":281,"type":20},641,[177],"A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head. It is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Migraines are caused by a series of events when the brain gets stimulated or activated, which causes the release of chemicals that cause pain. IPN10200 is a medication that stops the release of these chemical messengers.\n\nParticipants with episodic migraine (EM) or chronic migraine (CM) will be included in both Step 1 and Step 2. \"Headache days\" are when participants experience headaches that meet the criteria for a migraine or a headache without the additional migraine-specific symptoms. \"Migraine days\" occur when the headache displays clear migraine characteristics.\n\nThis study aims to determine:\n\n* The safety and efficacy of injecting IPN10200 directly into the muscles of the head and neck to prevent EM and CM,\n* The right amount (dose) of IPN10200 to inject at each point,\n* The total amount (dose) of IPN10200 that provides the best balance between safety and efficacy preventing migraines.\n\nParticipants will need to complete a daily electronic migraine Diary (eDiary) and questionnaires throughout the study. The total study duration for a participant will be up to 44 weeks.",[26,134],"2026-04-29",{"date":287,"type":35},"2026-05-05",{"date":289,"type":35},"2024-10-10",{"date":291,"type":20},"2027-10-31",{"name":293,"class":42},"Ipsen",166,{"id":296,"slug":4,"hasResults":10,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":302,"sex":15,"minAge":49,"maxAge":50,"enrollmentInfo":303,"targetDuration":4,"studyType":21,"phases":304,"briefSummary":305,"conditions":306,"keywords":307,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":319},"100535195","NCT06248671","Prophylactic Treatment With Atorvastatin for Episodic Migraine.","EpisodicStatinMig. A Multicentre, Triple Blind, Placebo Controlled, Parallel Group Study of Atorvastatin in Episodic Migraine","EStatinMig","Inclusion Criteria:\n\n* Age 18 to 65 years.\n* Signed informed consent.\n* Episodic migraine with or without aura according to ICHD-3 criteria.\n* At inclusion, patients should retrospectively have from 4 to 14 migraine attacks per month during the last 3 months. This frequency must be confirmed in the headache diary before randomisation to treatment.\n* Debut of migraine at least one year prior to inclusion based on information in the patient record or by careful examination of previous headache history.\n* Start of migraine before 50 years.\n* No use of other migraine prophylactics during the study.\n* For women of child-bearing potential, there must be no pregnancy or planned pregnancy during the study period, and use of highly effective contraception.\n\nAfter the baseline period, just before randomisation to the study drug, inclusion criteria will be evaluated once more, and the headache diary will be evaluated. If there are, according to the headache diary, fewer attacks than 4 or more than 14 per month, the baseline period can be extended to 8 weeks, and the patient can be randomized to a treatment then if there is a mean of 4-14 attacks per 4 weeks during the 8-week's period.\n\nExclusion Criteria:\n\n* Interval headache not distinguishable from migraine.\n* Chronic migraine, chronic tension-type headache, medication overuse headache or other headache occurring on ≥ 15 days\u002Fmonth.\n* Pregnancy, planning to get pregnant, inability to use contraceptives, and lactating.\n* Clinical information on or signs of cholestasis or decreased hepatic or renal function.\n* High degree of comorbidity and\u002For frailty associated with reduced life expectancy or high likelihood of hospitalization, at the discretion of the investigator.\n* Hypersensitivity to statins or previous use of statins.\n* History of angioneurotic oedema.\n* Use of medicines for migraine prophylaxis less than 4 weeks, or of botulinum toxin less than 16 weeks, prior to start of study.\n* Current use of antiviral treatment against hepatitis C.\n* Significant psychiatric illness.\n* Having tried ≥ 3 prophylactic drugs against migraine during the last 10 years.\n* Requiring detoxification from acute medication (triptans, opioids).\n* Consistently failing to respond to any acute migraine medication.\n* Alcohol or illicit drug dependence.\n* Inability to understand study procedures and to comply with them for the entire length of the study.\n* Treatment for hypothyroidism.\n* Lactose intolerance.",true,{"count":19,"type":20},[177],"The main objective of this study is to see whether the favorable preventative effect of Atorvastatin 40mg per day in episodic migraine, that was found previously in three smaller randomized controlled cross-over studies, can be confirmed in a larger, multicenter, randomized controlled parallel group study. In addition it will be investigated whether 1) there is an effect of a daily dose of 20mg Atorvastatin, 2) whether the favorable side effect profile, seen in previous studies, can be confirmed, and whether it is even better with the smaller dose, and 3) estimating the cost of Atorvastatin treatment, considering cost of medicine, cost of acute attack medicine, and cost of lost worktime.",[26],[135,308,309],"Atorvastatin","Randomized controlled trial","2026-02-16",{"date":312,"type":35},"2026-02-19",{"date":314,"type":35},"2024-05-01",{"date":316,"type":20},"2029-02-28",{"name":318,"class":69},"St. Olavs Hospital",6,{"id":321,"slug":4,"hasResults":10,"nctId":322,"briefTitle":323,"officialTitle":323,"acronym":324,"eligibilityCriteria":325,"healthyVolunteers":10,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":326,"targetDuration":328,"studyType":131,"phases":4,"briefSummary":329,"conditions":330,"keywords":332,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":349},"100605225","NCT07159750","Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine","EUREkA","Inclusion Criteria:\n\n* Migraine diagnosis according to ICHD-III.\n* Prescription of erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant or rimegepant according to prescriptor criteria and reimbursement criteria according to local regulations.\n* Signature of informed consent.\n\nExclusion Criteria:\n\n* Presence of headache different from migraine.\n* Active severe psychiatric condition or cognitive impairment which may affect the ability to consent patient's participation in the study.",{"count":327,"type":20},700,"2 Years","The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.",[135,26,331],"Chronic Migraine, Headache",[135,333,134,26,334,335,336,337,338,339],"Prevention","galcanezumab","erenumab","fremanezumab","eptinezumab","rimegepant","atogepant","2025-08-29",{"date":342,"type":35},"2025-09-08",{"date":344,"type":35},"2024-01-02",{"date":346,"type":20},"2026-01",{"name":348,"class":69},"Hospital Universitari Vall d'Hebron Research Institute",26,{"id":351,"slug":4,"hasResults":10,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":355,"eligibilityCriteria":356,"healthyVolunteers":10,"sex":15,"minAge":49,"maxAge":225,"enrollmentInfo":357,"targetDuration":4,"studyType":131,"phases":4,"briefSummary":359,"conditions":360,"keywords":362,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":70},"100583883","NCT06882122","Neurophysiological and Biomolecular Effects of Atogepant in Episodic Migraine","Neurophysiological and Biomolecular Effects of Atogepant in High Frequency Episodic Migraine (ATOM Project)","ATOM","Inclusion Criteria:\n\n* Individuals aged between 18 and 70;\n* Diagnosis of episodic migraine according to ICHD-3 criteria;\n* Monthly migraine days between 8 and 14 (high-frequency episodic migraine pattern) in the 3 months before screening;\n* Individuals naïve to CGRP-targeted treatments;\n* No more than one ongoing migraine preventive treatment with a stable dose for at least 3 months.\n\nExclusion Criteria:\n\n* Contraindications to atogepant;\n* History of serious psychiatric conditions;\n* Diagnosis of other primary or secondary headaches (only sporadic tension-type headache is allowed);\n* Medical conditions considered clinically significant by the investigator;\n* Chronic pain conditions that need chronic treatment;\n* Abuse of alcohol and\u002For drugs;\n* Pregnancy or breastfeeding.",{"count":358,"type":20},30,"The investigators aim to assess and compare neurophysiological and biochemical changes induced by a 3-month treatment with atogepant (60 mg daily) in patients with high-frequency episodic migraine (8-14 monthly migraine days). Evaluations will include neurophysiological assessments (High-Density EEG, nociceptive reflexes, and visual evoked potentials) and biomolecular profiling (gene expression of endocannabinoid catabolizing enzymes, CGRP and PACAP plasma levels, and headache-specific microRNAs). Outputs will contribute to defining predictors of atogepant response, elucidating its effects on brain connectivity, excitability, and CGRP\u002Fendocannabinoid pathways, and identifying alternative therapeutic targets for non-responders.",[361,26],"Migraine Disorder",[135,363,364,365,366,367,368],"Gepants","endocannabinoid system","MicroRNAs","Habituation deficit","Central sensitization","Functional Connectivity","2025-03-11",{"date":371,"type":35},"2025-03-18",{"date":373,"type":35},"2024-12-01",{"date":375,"type":20},"2026-04",{"name":377,"class":69},"IRCCS National Neurological Institute \"C. Mondino\" Foundation",{"id":379,"slug":4,"hasResults":10,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":383,"eligibilityCriteria":384,"healthyVolunteers":302,"sex":15,"minAge":49,"maxAge":385,"enrollmentInfo":386,"targetDuration":4,"studyType":131,"phases":4,"briefSummary":388,"conditions":389,"keywords":390,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":70},"100410739","NCT04628429","CGRP Inhibition, Autonomic Function, and Migraine","Autonomic Functions in Migraine Patients as a Function of Migraine Status and CGRP Inhibition","CGRP-1","Inclusion Criteria:\n\n* Chronic migraine according to ICHD-3\n* Episodic migraine without aura or with aura according to ICHD-3\n* Unsuccessful treatment with 3 or more established prophylactic drugs\n* Medicine costs are covered by health insurance\n* Healthy controls must be free from any diagnosed chronic disease or acute infection requiring medication\n\nExclusion Criteria:\n\n* Pregnancy and lactation\n* Neurosurgical interventions performed within the last 12 months\n* Coronary bypass surgery or revascularization procedures performed within the last 12 months\n* History of transient ischemic attacks (TIA), stroke, stable or unstable angina pectoris, myocardial infarction or uncontrolled hypertension\n* Known hypersensitivity to therapy with an anti-CGRP Antibodies\n* History of a disorder (other than migraine) that may affect the results of autonomic tests\n* Healthy controls must have no personal or family history of migraine","64 Years",{"count":387,"type":20},120,"The purpose of this clinical study is to better understand the function of the autonomic nervous system in patients with migraine. We aim to understand whether the autonomic functions change depending on the migraine status (i.e. whether they are between or during attacks) and whether the CGRP monoclonal antibody (mAb) class of drugs affects the autonomic functions. The aim is not to investigate the effect of CGRP-mAb on migraine frequency. Calcitonin gene-related peptide (CGRP) is a neurotransmitter in the nervous system that plays an essential role in the development of migraine headache. Monoclonal antibodies can block the function of this messenger substance. Several studies have shown that this blockade leads to a reduction in the frequency of migraine.\n\nIn addition to its role in migraine, CGRP also acts on the blood vessels and the autonomic nervous system. The autonomic nervous system is responsible for everything we have no control over in our body. This includes everything from heart rate and blood pressure to our digestion.",[26,134],[391,392,393,394,395,396,397,398],"Calcitonin gene-related peptide inhibition","Monoclonal antibodies","Autonomic function","Composite Autonomic Symptom Scale 31","Migraine Disability Assessment Scale","Depression Anxiety Stress Scales","Cardiovascular Autonomic Dysfunction","Headache Impact Questionnaire","2024-12-07",{"date":401,"type":35},"2024-12-10",{"date":403,"type":35},"2020-10-01",{"date":405,"type":20},"2026-12",{"name":407,"class":69},"Medical University of Vienna",{"id":409,"slug":4,"hasResults":10,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":413,"eligibilityCriteria":414,"healthyVolunteers":302,"sex":15,"minAge":16,"maxAge":415,"enrollmentInfo":416,"targetDuration":418,"studyType":131,"phases":4,"briefSummary":419,"conditions":420,"keywords":426,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":436,"locationsCount":70},"100567944","NCT06674772","Molecular Phenotyping of Migraine Patients According to Sex and Age Through CGRP Quantification","Fenotipado Molecular De Pacientes Con Migraña Según Edad Y Sexo a Través De La Cuantificación De CGRP En Saliva Para Realizar Medicina De Precisión: Estudio FAST","FAST","Inclusion Criteria:\n\n* Migraine patients according to ICHD-3 criteria\n* Healthy controls paired to patient age and sex, without headache and without first degree family history of headache.\n\nExclusion Criteria:\n\n* Presence of any major medical or neurological illness.\n* Presence of any salivary gland malfunction.\n* Abuse or dependence to tobacco, alcohol or any drug in the previous 12 months before the enrollment.\n* Active migraine preventive treatment.\n* Pregnant or breastfeeding female.","75 Years",{"count":417,"type":20},440,"1 Day","Patients will be asked to visit the study center 2 times, the first time for clinical assessment and a second time for sample collection. Healthy controls will only be asked to visit the study center for sample collection. A sample of blood and saliva will be collected in order to measure CGRP levels and DNA and hormone testing.",[421,135,422,423,259,26,424,331,425],"Headache (Migraine)","Migraine Headache","Migraine with Aura","Chronic Migraine Headache","Episodic Migraine Headache",[135,427,428],"CGRP","saliva","2024-11-11",{"date":431,"type":35},"2024-11-13",{"date":433,"type":35},"2022-11-29",{"date":435,"type":20},"2025-05",{"name":348,"class":69},{"id":438,"slug":4,"hasResults":10,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":10,"sex":15,"minAge":49,"maxAge":415,"enrollmentInfo":444,"targetDuration":446,"studyType":131,"phases":4,"briefSummary":447,"conditions":448,"keywords":449,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":459,"locationsCount":70},"100558296","NCT06549270","Biochemical Profiling of Migraine Patients","Unraveling the Spectrum of Migraine Resistant to Treatments: Searching for Novel Biological PHEnotypes and theRApeutic Approaches (SPHERA Project)","SPHERA_WP1_1","Inclusion Criteria:\n\n* male and female patients aged 18 to 75 years\n* diagnosis of episodic migraine or chronic migraine according to ICHD-3 criteria\n* for episodic migraine: 8-14 monthly migraine days in the previous 3 months\n* diagnosis of resistant migraine defined by: i) having failed at least 3 classes of migraine preventatives and ii) suffering from at least 8 debilitating monthly headache days for at least 3 consecutive months\n* patients naive to CGRP targeting treatments\n\nExclusion Criteria:\n\n* history of major psychiatric or other neurological conditions\n* diagnosis of other primary or secondary headache disorders (only sporadic tension-type headache is allowed if the patients can clearly differentiate between the 2 types of headaches)\n* changes in ongoing preventive treatment (if any) in the previous 3 months\n* clinically significant medical conditions\n* chronic pain conditions\n* alcohol and\u002For drug abuse\n* pregnancy or lactation",{"count":445,"type":20},100,"3 Months","Aim of the study was to assess a potential dysfunction of the endocannabidiome system (eCBome) in migraine patients. Migraine patients who will undergo preventive therapy with monoclonal antibodies directed against the calcitonin gene related peptide (mAbs) will be evaluated through a deep phenotyping of peripheral neurochemical biomarkers (eCBome, neuropeptides, cytokines and kynurenine levels, and microRNAs expression).\n\nPrimary aim is to assess baseline differences among those patients who achieved a reduction of monthly migraine days \\>\u002F= 50% after three months of tretament (namely Responders) and those who did not (namely Non-responders).",[257,134,26],[58,450,451,364],"anti CGRP mABs","calcitonin gene related peptide","2024-09-01",{"date":454,"type":35},"2024-09-05",{"date":456,"type":35},"2023-05-10",{"date":458,"type":20},"2026-05",{"name":377,"class":69},{"id":461,"slug":4,"hasResults":10,"nctId":462,"briefTitle":463,"officialTitle":441,"acronym":464,"eligibilityCriteria":465,"healthyVolunteers":10,"sex":15,"minAge":49,"maxAge":415,"enrollmentInfo":466,"targetDuration":468,"studyType":131,"phases":4,"briefSummary":469,"conditions":470,"keywords":471,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":479,"completionDateStruct":480,"leadSponsor":481,"locationsCount":70},"100559305","NCT06562400","Searching for Novel Therapeutic Approaches in Migraine Patients Resistant to Treatments","SPHERA_WP2","Inclusion Criteria:\n\n* male and female patients aged 18 to 75 years\n* diagnosis of episodic migraine or chronic migraine according to ICHD-3 criteria\n* for episodic migraine: 8-14 monthly migraine days in the previous 3 months\n* diagnosis of resistant migraine, defined by having failed at least 3 classes of migraine preventatives and suffer from at least 8 debilitating monthly headache days for at least 3 consecutive months\n* patients naive to CGRP targeting treatments\n\nExclusion Criteria:\n\n* history of major psychiatric or other neurological conditions\n* diagnosis of other primary or secondary headache disorders (only sporadic tension-type headache is allowed if the patients can clearly differentiate between the 2 types of headaches)\n* clinically significant medical conditions\n* chronic pain conditions\n* alcohol and\u002For drug abuse\n* pregnancy or lactation",{"count":467,"type":20},45,"6 Months","Primary working hypothesis is that NON-responders to mAbs bear a dysfunction of the endocannabidiome system (eCBome), as suggested by pre-clinical and clinical data by our group.\n\nThey will be identified as patients showing a reduction of monthly migraine days \\\u003C 50% after three months of treatment.\n\nThe clinical, biochemical and neurofunctional impact of novel therapeutic approaches expected to interfere with eCBome will be evaluated in NON-responder patients",[257,134,26],[58,450,451,364,472,473,474,475],"HD EEG","functional MRI","brain connectivity","miocrobiome","2024-08-17",{"date":478,"type":35},"2024-08-20",{"date":456,"type":35},{"date":458,"type":20},{"name":377,"class":69},{"id":483,"slug":4,"hasResults":10,"nctId":484,"briefTitle":485,"officialTitle":441,"acronym":486,"eligibilityCriteria":487,"healthyVolunteers":10,"sex":15,"minAge":49,"maxAge":415,"enrollmentInfo":488,"targetDuration":468,"studyType":131,"phases":4,"briefSummary":489,"conditions":490,"keywords":491,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":492,"startDateStruct":493,"completionDateStruct":494,"leadSponsor":495,"locationsCount":70},"100559306","NCT06562413","Searching for Novel Biological Phenotypes in Migraine Patients Resistant to Treatments","SPHERA_WP1_2","Inclusion Criteria:\n\n* male and female patients aged 18 to 75 years\n* diagnosis of episodic migraine or chronic migraine according to ICHD-3 criteria\n* for episodic migraine: 8-14 monthly migraine days in the previous 3 months\n* diagnosis of resistant migraine, defined by having failed at least 3 classes of migraine preventatives and suffer from at least 8 debilitating monthly headache days for at least 3 consecutive months\n* patients naive to CGRP targeting treatments\n\nExclusion Criteria:\n\n* history of major psychiatric or other neurological conditions\n* diagnosis of other primary or secondary headache disorders (only sporadic tension-type headache is allowed if the patients can clearly differentiate between the 2 types of headaches)\n* changes in ongoing preventive treatment (if any) in the previous 3 months\n* clinically significant medical conditions\n* chronic pain conditions\n* alcohol and\u002For drug abuse\n* pregnancy or lactation",{"count":445,"type":20},"The investigators aim to define the neurofunctional phenotype of migraine patients who did not respond to at least 3 preventive treatments, including monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) pathway (NON-responders).\n\nPrimary aim will be to assess and compare changes in functional resting-state connectivity at baseline and after three months of mAbs treatment between patients who will achieve a reduction of monthly migraine days \\>\u002F= than 50% (namely Responders) and those who will not (namely Responders).\n\nThe 2 groups will undergo a neurofunctional profile by means of High Density-electroencephalogram (HD-EEG) and functional-magnetic resonance imaging (fMRI).",[257,134,26],[58,450,451,472,473,474],{"date":478,"type":35},{"date":456,"type":35},{"date":458,"type":20},{"name":377,"class":69},""]